{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:34:54Z","timestamp":1715646894389},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,12]]},"DOI":"10.7759\/cureus.60161","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T01:55:01Z","timestamp":1715565301000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Midostaurin: Role of Avapritinib in Managing Systemic Mastocytosis"],"prefix":"10.7759","author":[{"given":"Ngowari","family":"Pokima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Khattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praneeth R","family":"Keesari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nnedindu","family":"Asogwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent P","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017, 129:1420-7. 10.1182\/blood-2016-09-731893","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann K","year":"2016","unstructured":"Hartmann K, Escribano L, Grattan C, et al.. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016, 137:35-45. 10.1016\/j.jaci.2015.08.034","journal-title":"J Allergy Clin Immunol"},{"key":"ref3","article-title":"The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. Leukemia","author":"Li W","year":"2022","unstructured":"Li W. The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. Leukemia. Exon Publications, Brisbane (AU); 2022."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow K","year":"2014","unstructured":"Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014, 34:283-95. 10.1016\/j.iac.2014.01.003","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib J","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, et al.. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016, 374:2530-41. 10.1056\/NEJMoa1513098","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent P","year":"2007","unstructured":"Valent P, Akin C, Escribano L, et al.. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007, 37:435-53. 10.1111\/j.1365-2362.2007.01807.x","journal-title":"Eur J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny HP","year":"2001","unstructured":"Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001, 25:543-51. 10.1016\/S0145-2126(01)00021-2","journal-title":"Leuk Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199809000-00013","article-title":"Diagnostic value of immunostaining for tryptase in patients with mastocytosis","volume":"22","author":"Horny HP","year":"1998","unstructured":"Horny HP, Sillaber C, Menke D, et al.. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998, 22:1132-40. 10.1097\/00000478-199809000-00013","journal-title":"Am J Surg Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz R","year":"2001","unstructured":"Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, F\u00f6dinger M. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001, 113:357-64. 10.1046\/j.1365-2141.2001.02783.x","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-60309-3_10","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1, or with PCM1-JAK2","author":"Beham-Schmid C","year":"2020","unstructured":"Beham-Schmid C, Schmitt-Graeff A. Myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1, or with PCM1-JAK2. Bone Marrow Biopsy Pathology. Essentials of Diagnostic Pathology. Springer, Berlin, Heidelberg; 2020. 10.1007\/978-3-662-60309-3_10"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim KH","year":"2009","unstructured":"Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009, 84:790-4. 10.1002\/ajh.21561","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0450-8","article-title":"Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis","volume":"33","author":"L\u00fcbke J","year":"2019","unstructured":"L\u00fcbke J, Naumann N, Kluger S, et al.. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia. 2019, 33:1195-205. 10.1038\/s41375-019-0450-8","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus P","year":"2002","unstructured":"Casassus P, Caillat-Vigneron N, Martin A, et al.. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002, 119:1090-7. 10.1046\/j.1365-2141.2002.03944.x","journal-title":"Br J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in advanced systemic mastocytosis","volume":"374","author":"Chandesris MO","year":"2016","unstructured":"Chandesris MO, Damaj G, Canioni D, et al.. Midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016, 374:2605-7. 10.1056\/NEJMc1515403","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112017","article-title":"Avapritinib, a potent and selective inhibitor of KIT D816V, improves symptoms of advanced systemic mastocytosis (AdvSM): analyses of patient reported outcomes (PROs) from the phase 1 (EXPLORER) study using the (AdvSM) symptom assessment form (AdvSM-SAF), a new PRO questionnaire for (AdvSM)","volume":"132","author":"Gotlib JR","year":"2018","unstructured":"Gotlib JR, Radia D, DeAngelo DJ, et al.. Avapritinib, a potent and selective inhibitor of KIT D816V, improves symptoms of advanced systemic mastocytosis (AdvSM): analyses of patient reported outcomes (PROs) from the phase 1 (EXPLORER) study using the (AdvSM) symptom assessment form (AdvSM-SAF), a new PRO questionnaire for (AdvSM). Blood. 2018, 132:351. 10.1182\/blood-2018-99-112017","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91439-8_10","article-title":"Midostaurin: a multiple tyrosine kinases inhibitor in acute myeloid leukemia and systemic mastocytosis","author":"Schlenk RF","year":"2018","unstructured":"Schlenk RF, Kayser S. Midostaurin: a multiple tyrosine kinases inhibitor in acute myeloid leukemia and systemic mastocytosis. Small Molecules in Hematology. Springer, Cham, Switzerland; 2018. 212:199-214. 10.1007\/978-3-319-91439-8_10"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans EK","year":"2017","unstructured":"Evans EK, Gardino AK, Kim JL, et al.. A precision therapy against cancers driven by KIT\/PDGFRA mutations. Sci Transl Med. 2017, 9:10.1126\/scitranslmed.aao1690","journal-title":"Sci Transl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo DJ","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, et al.. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021, 27:2183-91. 10.1038\/s41591-021-01538-9","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01843-7","article-title":"MPN- 395: efficacy and safety of\u2264 200 mg avapritinib in patients with advanced systemic mastocytosis: pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies","volume":"21","author":"Radia D","year":"2021","unstructured":"Radia D, DeAngelo D, Deininger MW, et al.. MPN- 395: efficacy and safety of\u2264 200 mg avapritinib in patients with advanced systemic mastocytosis: pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies. Clin Lymphoma Myeloma Leuk. 2021, 21:367-8. 10.1016\/S2152-2650(21)01843-7","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter A","year":"2022","unstructured":"Reiter A, Gotlib J, \u00c1lvarez-Twose I, et al.. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022, 36:2108-20. 10.1038\/s41375-022-01615-z","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1509","article-title":"Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis","volume":"18","author":"Pilkington H","year":"2022","unstructured":"Pilkington H, Smith S, Roskell N, Iannazzo S. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis. Future Oncol. 2022, 18:1583-94. 10.2217\/fon-2021-1509","journal-title":"Future Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146873","article-title":"Efficacy of avapritinib in patients with advanced systemic mastocytosis: hematologic and bone marrow responses from the phase 2 open-label, single-arm, Pathfinder study","volume":"138","author":"George TI","year":"2021","unstructured":"George TI, Karner KH, Moser KA, et al.. Efficacy of avapritinib in patients with advanced systemic mastocytosis: hematologic and bone marrow responses from the phase 2 open-label, single-arm, Pathfinder study. Blood. 2021, 138:2565. 10.1182\/blood-2021-146873","journal-title":"Blood"},{"key":"ref23","unstructured":"FDA approves avapratinib for advanced systemic mastocytosis. FDA. (2021). https.\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-avapritinib-advanced-systemic-mastocytosis."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/250488-beyond-midostaurin-role-of-avapritinib-in-managing-systemic-mastocytosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T01:55:09Z","timestamp":1715565309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/250488-beyond-midostaurin-role-of-avapritinib-in-managing-systemic-mastocytosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,12]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.60161","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,12]]}}}